



HAL
open science

Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations

Eve Todesco, C. Charpentier, M. Bertine, M. Wirden, A. Storto, N. Desire, M. Grude, T. Nguyen, S. Sayon, Y. Yazdanpanah, et al.

► To cite this version:

Eve Todesco, C. Charpentier, M. Bertine, M. Wirden, A. Storto, et al.. Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. *HIV Medicine*, 2017, 10.1111/hiv.12508 . hal-01518302

HAL Id: hal-01518302

<https://hal.sorbonne-universite.fr/hal-01518302>

Submitted on 4 May 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Disparities in HIV-1 Transmitted Drug Resistance detected by**
2 **UltraDeep Sequencing among Men having Sex with Men and**
3 **Heterosexual Populations**

4 **Running head: HIV-1 Transmitted Drug Resistance**

5 E TODESCO ^{1,2}, C CHARPENTIER ^{3,4,5}, M BERTINE ^{3,4,5}, M Wirden ^{1,2}, A STORTO ⁵, N DESIRE ¹, M
6 GRUDE ¹, T NGUYEN ^{1,2}, S SAYON ^{1,2}, Y YAZDANPANAH ^{3,4,6}, C KATLAMA ^{1,7}, D DESCAMPS ^{3,4,5},
7 V CALVEZ ^{1,2}, AG MARCELIN ^{1,2}

8 **Institutional affiliations:**

9 ¹ Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et
10 de Santé Publique (IPLESP UMRS 1136), F75013, Paris, France, ² Department of Virology,
11 Hôpital Pitié-Salpêtrière, AP-HP, F75013, Paris, France, ³ INSERM, IAME, UMR 1137,
12 Sorbonne Paris Cité, F-75018 Paris, France, ⁴ Univ Paris Diderot, IAME, UMR 1137, F-75018
13 Paris, France, ⁵ AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018,
14 Paris, France, ⁶ AP-HP, Hôpital Bichat-Claude Bernard, Department of Infectious Diseases, F-
15 75018 Paris, France, ⁷ Department of Infectious Diseases, Hôpital Pitié-Salpêtrière, AP-HP,
16 F75013, Paris, France

17 **Word counts of the abstract: 169 words**

18 **Word counts of the text: 1463 words**

19

20 **Corresponding author:**

21 Eve Todesco, Department of Virology, Bât CERVI, Hôpital Pitié-Salpêtrière, 83 Bd de l'Hôpital, 75013 Paris,
22 France. Email: eve.todesco@aphp.fr. Fax: 33 1 42177411. Phone: 33 1 42177426

23 **Keywords:** HIV; Deep Sequencing; Minority resistant variants; Transmitted Drug Resistance.

24

25 **Abstract**

26 **Objectives**

27 Transmitted Drug Resistance (TDR) can impair first-line antiretroviral therapy response. It
28 has been shown by Sanger sequencing that TDR was more common among Men having Sex
29 with Men (MSM) in treatment-naive patients chronically infected with HIV type 1 (HIV-1).
30 We aimed to compare the presence of TDR mutations between two groups of HIV-1
31 transmission.

32 **Methods**

33 We studied, by Sanger Sequencing and UltraDeep Sequencing (UDS), the presence of
34 resistance mutations, both in majority (>20%) and in minority (1-20%) proportions, among
35 70 treatment-naive MSM and 70 treatment-naive heterosexual patients recently screened
36 positive for HIV-1.

37 **Results**

38 Between the two groups, global prevalence of TDR was not significantly different either by
39 Sanger or by UDS. Nevertheless, a higher frequency of nucleoside reverse transcriptase
40 inhibitors-TDR was observed among heterosexual patients ($p=0.04$). There was also a trend
41 for a higher frequency of TDR among MSM infected with HIV-1 subtype B compared to MSM
42 infected with HIV-1 subtype non-B ($p=0.06$).

43 **Conclusions**

44 UDS allows sensitive monitoring of TDR, and highlights some disparities between groups of
45 transmission.

46

47

48 **INTRODUCTION**

49 Transmitted Drug Resistance (TDR) detection can impair first-line antiretroviral
50 therapy response. Indeed, the presence of TDR-mutations can conduct to a higher risk of
51 virological failure if the affected drugs are introduced [1]. The surveillance of HIV type 1
52 (HIV-1) TDR is widely recommended and it has been shown that TDR was more common
53 among Men having Sex with Men (MSM) and among patients infected with subtype B virus
54 in the 2010/2011 French survey study conducted in antiretroviral-naïve chronically HIV-1-
55 infected patients by standard sequencing techniques [2]. Standard sequencing detects viral
56 populations accounting for more than 15-20% of viral population. However, HIV-1 minority
57 resistant variants can be a source of virological failure: it was mainly shown for first line
58 regimens based on first generation Non Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
59 [3,4]. The next generation sequencing technologies are able to detect these minority
60 variants. Nevertheless, few data are available on presence of minority TDR variants in
61 different groups of HIV transmission, treatment-naïve patients [5]. The use of UltraDeep
62 Sequencing (UDS) could evidence larger difference of TDR between groups of transmission
63 than Sanger sequencing does.

64 The aim of the study was to compare the presence of TDR mutations, both in majority
65 (>20%) and in minority (1-20%) proportions, between treatment-naïve MSM and treatment-
66 naïve heterosexual HIV-1 chronically infected patients.

67 **METHODS**

68 *Patients.* The study enrolled 70 treatment-naïve heterosexual patients and 70 treatment-
69 naïve MSM recently diagnosed for HIV-1. We performed Sanger Sequencing (n=140; Reverse
70 Transcriptase gene (RT) and Protease gene (PR)) and UDS (n=70 RT and n=70 PR sequences
71 among MSM group; n=54 RT and n=67 PR sequences among heterosexual group). Patients

72 were followed by Department of Infectious Diseases of Pitié-Salpêtrière and Bichat Claude
73 Bernard hospitals (Paris, France). Informations were obtained from the existing electronic
74 database or medical record. Patients were informed that their demographic and clinical data
75 will be recorded during their follow up and could be used for retrospective studies and gave
76 their consent. This study was approved by the Agence Nationale de Recherches sur le SIDA
77 et les hépatites virales (ANRS) AC11 Ethics Committee.

78 *Sanger sequencing.* The first sample of plasma positive for HIV-1 was used for performing
79 genotypic resistance test. RT and PR genotypic analysis was conducted according to the
80 ANRS consensus method [6]. PR and RT mutations were identified using the consensus
81 statement of the list for the TDR genotypic surveillance. [7] Additional interpretations were
82 performed with the International AIDS Society (IAS) list (figure) and the last version of ANRS
83 algorithm (www.hivfrenchresistance.org). Any sequences found to have a mixture of wild
84 type and mutant amino acid residues at single positions were considered to have the
85 mutant.

86 The subtype determination was performed using the HIV Module of SmartGene (SmartGene,
87 Zug, Switzerland) whose methodology is based on Basic Local Alignment Search Tool
88 (BLAST).

89 *UDS.* The steps until pyrosequencing on GS Junior (Roche 454® Life Sciences, Branford, CT,
90 United States) were previously described [8]. Primers used are available on
91 hiv.frenchresistance.org. Pyrosequencing was performed according to manufacturer
92 recommendations [9]. GS Amplicon Variant Analyzer (Roche 454® Life Sciences, Branford,
93 CT, United States) was used to analyze the UDS results. Alignments were checked.

94 *Statistical Analysis.* To compare MSM and heterosexual populations baseline
95 characteristics, Chi 2 and Mann-Whitney tests were used for categorical (subtype) and
96 continuous variables (age, viral load, CD4 cells count), respectively.

97 Global prevalence and prevalence of TDR mutations by antiretroviral classes were compared
98 by a Chi 2 test between the two groups.

99 **RESULTS**

100 An average of 5198 reads per nucleotide position was amplified and the average error rates
101 in controls (cellular clone 8E5) were 0.0012 and 0.0032 for RT and PR, respectively. These
102 results allowed for accurate detection of variants down to 1% [10, 11].

103 Characteristics of patients are as follows: the median age was 36.3 years among the 70 MSM
104 patients and 35.4 years among the 70 heterosexual patients (60% female), without
105 significant difference between the two populations. Sixty percent of the patients were
106 infected by HIV-1 subtype B among the MSM group whereas 94% were infected by HIV-1
107 subtype non-B among the heterosexual group. Among the MSM patients, median viral load
108 (VL) was 4.9 log₁₀ copies/mL (IQR=4.4-5.4) and median CD4 cell count was 498/mm³
109 (IQR=347-585). Among the heterosexual patients, median VL was 4.9 log₁₀ copies/mm³
110 (IQR=4.3-5.3) and median CD4 cell count was 348/mm³ (IQR=208-497). The levels of HIV-1 VL
111 were similar between the two groups, but median CD4 cell count was higher among MSM
112 than among heterosexual patients (p= 0.0016).

113 Global prevalence of TDR and prevalence by drug classes are presented in Table 1. A total
114 concordance was found between Sanger sequencing and UDS for all mutations detected on
115 bulk.

116 Sanger sequencing detected two Nucleoside Reverse Transcriptase Inhibitors (NRTI)-TDR
117 mutations in virus genome of one MSM patient (M41L and T215C) and one in virus genome
118 of three heterosexual patients (M41L or T215E or M184I/V); one NNRTI-TDR mutation was
119 detected in virus genome of two MSM patients (K103N) and one in virus genome of three
120 heterosexual patients (K103N or Y181I or Y188L) and one Protease Inhibitors (PI)-TDR
121 mutation was detected in virus genome of one heterosexual patient (I85V).

122 Within each group, we retrieved a higher prevalence of TDR mutations when UDS was
123 performed: prevalence of TDR was 18.6% (95%CI=9.4%-27.7%) with UDS *versus* 4.3%
124 (95%CI=0.0%-9.1%) with Sanger Sequencing among MSM and 22.8% (95%CI=12.7%-33.0%)
125 with UDS *versus* 7.1% (95%CI=0.9%-13.4%) with Sanger Sequencing among heterosexual
126 population.

127 Among the MSM, the increased TDR detected by UDS was observed especially for NNRTI and
128 PI (10.0% *versus* 2.9% by Sanger sequencing and 7.1% *versus* 0.0% by Sanger sequencing,
129 respectively) while it was mainly for NRTI and PI among the heterosexual patients (14.8%
130 *versus* 4.3% by Sanger sequencing and 10.4% *versus* 1.4% by Sanger sequencing,
131 respectively).

132 The rate of TDR mutations only detected by UDS was low: between 1.1% and 4.8% for NRTI,
133 1.1% and 1.5% for NNRTI and 1.1% and 7.0% for PI (Figure 1).

134 Between the two groups, global prevalence of TDR was not significantly different either by
135 Sanger or by UDS. Nevertheless, a higher frequency of NRTI-TDR was observed among
136 heterosexual patients than among MSM (14.8% *versus* 4.3%, respectively; $p=0.04$).

137 We also retrieved a trend for a higher frequency of TDR among MSM patients infected with
138 HIV-1 subtype B compared to MSM patients infected with HIV-1 subtype non-B (26.2%
139 ($n=11/42$) *versus* 7.1% ($n=2/28$) with UDS ($p=0.06$), data not shown).

140 In addition, some resistance mutations, not considered in the list for TDR genotypic
141 surveillance, but considered as major in some genotypic algorithms, were identified as
142 minority variants. For instance, three K65E mutations were detected by UDS. With the last
143 version of ANRS algorithm, the prevalence of resistance to the recommended drugs
144 (European AIDS Clinical Society EACS) detected by UDS for NRTI, NNRTI and IP were 2.9%,
145 12.8% and 7.1% among MSM patients and 11.1%, 5.6% and 11.9% among heterosexual
146 patients, respectively.

147 DISCUSSION

148 Higher prevalence of TDR was observed in antiretroviral-naive chronically HIV-1-infected
149 MSM and heterosexual populations when UDS was used compared to population
150 sequencing. Indeed, these powerful techniques could improve the detection of HIV-1-TDR.

151 In the present study, UDS allowed to detect a higher frequency of NRTI-TDR among
152 heterosexual population than among MSM patients, whereas based on the results of CD4
153 cell count, the date of transmission seems to be older in the heterosexual population.

154 Usually, the more time goes by and the less TDR are detected. However, most thymidine
155 analogue mutations were found to be highly stable without selection pressure. It has been
156 shown that NNRTI and PI mutations were, globally, less persistent than NRTI mutations,
157 maybe because of a negative impact on viral fitness [11,12].

158 Otherwise, UDS evidenced a higher frequency of TDR in subtype B versus subtype non-B
159 viruses among MSM patients. This is consistent with what has been previously shown by
160 Sanger sequencing in the Odyssey study on antiretroviral-naive chronically HIV infected
161 patients and in the study on French patients diagnosed at the time of primary HIV-1
162 infection [2,13].

163 We obviously need further investigations for NRTI, second generation NNRTI and PI-based
164 regimen, as the impact of minority TDR mutations on first generation NNRTI is already well
165 known [3,4]. Furthermore, minority TDR mutations on integrase strand transfer inhibitors
166 have not been studied in this work. As few data are available on this subject and still
167 controversial, more studies are needed [14,15]. Nevertheless, an increase of TDR is
168 predictable for this therapeutic class with the extensive use of these drugs and should be
169 monitored in the future.

170 In conclusion, UDS allows sensitive monitoring of TDR, and is able to evidence some
171 disparities of TDR between HIV groups of transmission. In the present study, next generation
172 sequencing technologies probably detect minority resistant variants that are disappearing.
173 The impact of these minority TDR mutations for certain therapeutic classes and in particular
174 for the more recent drugs is unknown and should be further evaluated.

175

176 **Acknowledgments:**

177 We thank Géraldine Lemallier and Philippe Grange for their technical assistance, and ROCHE
178 DIAGNOSTICS FRANCE.

179 *Conflicts of interest:* All authors declare that they have no conflicts of interest.

180 *Funding:* This work was supported by the Agence Nationale de Recherches sur le SIDA et les
181 hépatites virales (ANRS).

182

183

184 **References**

- 185 1. Wittkop L, Günthard HF, de Wolf F, *et al.* Effect of transmitted drug resistance on virological and
186 immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN
187 joint project): a European multicohort study. *Lancet Infect Dis* 2011; **11(5)**:363–71.
- 188 2. Descamps D, Assoumou L, Chaix M-L, *et al.* National sentinel surveillance of transmitted drug
189 resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade:
190 2001-2011. *J Antimicrob Chemother* 2013; **68(11)**:2626–31.
- 191 3. Li JZ, Paredes R, Ribaud HJ, *et al.* Low-frequency hiv-1 drug resistance mutations and risk of
192 nrti-based antiretroviral treatment failure: A systematic review and pooled analysis. *JAMA*.
193 2011; **305(13)**:1327–35.
- 194 4. Cozzi-Lepri A, Noguera-Julian M, Giallonardo FD, *et al.* Low-frequency drug-resistant HIV-1 and
195 risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control
196 study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother* 2015;
197 **70(3)**:930–40.
- 198 5. Cunningham E, Bibby D, Lythgow K, *et al.* Enhanced surveillance of HIV-1 transmitted drug
199 resistance and transmission clusters in recently infected UK MSM. *International Workshop on*
200 *Antiviral Drug Resistance 2014*. Berlin, Germany, June 2014.
- 201 6. Descamps D, Delaugerre C, Masquelier B, *et al.* Repeated HIV-1 resistance genotyping external
202 quality assessments improve virology laboratory performance. *J Med Virol* 2006; **78(2)**:153–60.
- 203 7. Bennett DE, Camacho RJ, Otelea D, *et al.* Drug resistance mutations for surveillance of
204 transmitted HIV-1 drug-resistance: 2009 update. *PLoS One* 2009; **4(3)**: e4724.


- 205 8. Todesco E, Rodriguez C, Morand-Joubert L, *et al.* Improved detection of resistance at failure to a
206 tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. *J Antimicrob*
207 *Chemother* 2015; **70(5)**:1503–6.
- 208 9. Daigle D, Simen BB, Pochart P. High-throughput sequencing of PCR products tagged with
209 universal primers using 454 life sciences systems. *Curr Protoc Mol Biol* 2011; **96**: 7.5.1–7.5.14.
- 210 10. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra
211 with ultra-deep pyrosequencing: application to HIV-1 drug resistance. *Genome Res* 2007;
212 **17(8)**:1195–201.
- 213 11. Castro H, Pillay D, Cane P, *et al.* Persistence of HIV-1 transmitted drug resistance mutations. *J*
214 *Infect Dis* 2013; **208(9)**:1459–63.
- 215 12. Wirden M, Delaugerre C, Marcelin AG, *et al.* Comparison of the dynamics of resistance-
216 associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse
217 transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination
218 therapy. *Antimicrob Agents Chemother* 2004; **48(2)**:644–7.
- 219 13. Frange P, Assoumou L, Descamps D, *et al.* HIV-1 subtype B-infected MSM may have driven the
220 spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line
221 strategies. *J Antimicrob Chemother* 2015; **70(7)**:2084–9.
- 222 14. Charpentier C, Lee GQ, Rodriguez C, *et al.* Highly frequent HIV-1 minority resistant variants at
223 baseline of the ANRS 139 TRIO trial had a limited impact on virological response. *J Antimicrob*
224 *Chemother* 2015; **70(7)**:2090–6.
- 225 15. Armenia D, Vandenbroucke I, Fabeni L, *et al.* Study of genotypic and phenotypic HIV-1 dynamics
226 of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454
227 pyrosequencing. *J Infect Dis* 2012; **205(4)**:557–67.

Table 1: Global prevalence of Transmitted Drug Resistance and by drug classes among the two groups: MSM and heterosexual patients.

	Sanger sequencing			UltraDeep sequencing		
	MSM n=70	Heterosexual population n=70	p value	MSM n=70	Heterosexual population RT n=54 Protease n=67	p value
Global prevalence of TDR [95% CI]	n= 3 4.3% [0.0%-9.1%]	n= 5 7.1% [0.9%-13.4%]	0.47	n= 13 18.6% [9.4%-27.7%]	n=16 22.8% [12.7%-33.0%]	0.53
Prevalence of NRTI-TDR [95% CI]	n= 1 1.4% [0.0%-4.2%]	n= 3 4.3% [0.0%-9.2%]	0.31	n= 3 4.3% [0.0%-9.1%]	n= 8 14.8% [5.3%-24.4%]	0.04
Prevalence of NNRTI-TDR [95% CI]	n= 2 2.9% [0.0%-6.8%]	n= 3 4.3% [0.0%-9.2%]	0.65	n= 7 10.0% [2.9%-17.1%]	n= 4 7.4% [0.4%-14.5%]	0.61
Prevalence of PI-TDR [95% CI]	n=0 0.0%	n= 1 1.4% [0.0%-4.3%]	0.32	n= 5 7.1% [1.1%-13.2%]	n= 7 10.4% [3.1%-17.8%]	0.49

CI: Confidence Interval; MSM: Men Men having Sex with Men; NRTI: Nucleoside Reverse Transcriptase Inhibitors; NNRTI: Non NRTI; PI: Protease Inhibitors; TDR: Transmitted Drug Resistance

Figure 1. Percentage of Transmitted Drug Resistance mutations only detected by UDS among the two groups: MSM and heterosexual patients



^a: Each bar represents one patient; * Major IAS drug resistance mutations

MSM: Men having Sex with Men; NRTI: Nucleoside Reverse Transcriptase Inhibitors; NNRTI: Non NRTI; PI: Protease Inhibitors; UDS: UltraDeep Sequencing